henhaobio
Sign in

Scientific ReportsBiochemistryPeer-reviewed journal article

HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2

Flavio AlvareziD, Florence LarrousiD, Ariel MéchalyiD, Benjamin BardiauxiD, Quentin GOOR, Ahmed HaouziD, Blandine Séon‐Méniel, Rodolphe Alves de SousaiD, Stéphane BourgiD, Didier DesmaëleiD, Bruno FigadèreiD, Nicolas WolffiD, Hélène Munier‐LehmanniD, Célia Caillet‐SaguyiD

PDFDOIPreprint

Abstract

The SARS-CoV-2 E protein through its C-terminal PDZ-binding motif (PBM) interacts with several host PDZ-containing proteins, including the ZO-1 protein via its PDZ2 domain, thereby contributing to viral pathogenesis. Targeting this interaction represents a potential therapeutic strategy. In this study, we determined the X-ray structure of the E PBM peptide in complex with the ZO-1 PDZ2 domain at 1.7 [A] resolution. The structure revealed a domain-swapped dimer conformation of ZO-1 PDZ2, with the E PBM peptide conventionally bound within the PDZ domains canonical binding groove exhibiting key interactions characteristic of type II PBM-PDZ interactions. To identify potential inhibitors of the E PBM/ZO-1 PDZ2 interaction, we performed a HTRF screening using a protein-protein interaction-focused library of 1,000 compounds. This led to the identification of 36 hits that disrupted this interaction. Subsequent cytotoxicity and dose- response assays narrowed the selection to 14 promising compounds. Docking simulations showed that some compounds bind within or near the PBM-binding pocket, supporting a competitive mechanism of interaction inhibition, while others bind at a central interface between the two PDZ monomers, suggesting an inhibition of dimerization, which in turn prevents PBM binding. Thus, the ZO-1 PDZ2-E PBM interaction can be inhibited through both direct and indirect mechanisms. Finally, antiviral assays using a NanoLuciferase-expressing recombinant SARS-CoV-2 demonstrated that one compound, C19, significantly reduced viral replication, highlighting its potential as a candidate for further therapeutic development. HighlightsO_LICrystal structure reveals the binding determinant of E protein PBM to ZO-1 PDZ2 dimer C_LIO_LIHTRF screening identified 36 inhibitors of the E-ZO-1 protein interaction C_LIO_LIDocking revealed dual mechanisms: PBM groove binding and dimer interface disruption C_LIO_LICompound C19 reduced SARS-CoV-2 replication in a NanoLuc reporter assay C_LIO_LITargeting E-ZO-1 interaction may prevent barrier loss and systemic COVID-19 effects C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=186 SRC="FIGDIR/small/665136v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@1f900bcorg.highwire.dtl.DTLVardef@9f470aorg.highwire.dtl.DTLVardef@f0ec19org.highwire.dtl.DTLVardef@11c9115_HPS_FORMAT_FIGEXP M_FIG C_FIG

Citations
1
FWCI
0.76
Field percentile
top 23%

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.